RT Journal Article
T1 Prognostic Outcomes of Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Retrospective Comparative Cohort Study
A1 Salido-Vallejo, Rafael
A1 Escribano-Castillo, Lourdes
A1 Antoñanzas, Javier
A1 Roldán-Córdoba, Claudia
A1 Velez Garcia-Nieto, Antonio
A1 Aguado-Gil, Leyre
K1 Immunosuppression
K1 Immunocompromised
K1 Solid organ transplant
K1 Cutaneous squamous cell carcinoma
K1 Prognosis
K1 Recurrence; metastasis
K1 Non-melanoma skin cancer
K1 Inmunosupresión
K1 Inmunocomprometidos
K1 Trasplante de órganos sólidos
K1 Escamoso cutáneo carcinoma de células
K1 Pronóstico
K1 Cáncer de piel no melanoma
K1 Reaparición
K1 Metástasis
AB Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous neoplasm, and its incidence is on the rise. While most cSCCs have an excellent prognosis, certain risk factors, especially immunosuppression, have been associated with higher rates of local recurrence (LR), metastasis, and poor prognosis. This study aims to assess the risk factors for LR and metastasis development in cSCC among solid organ transplant recipients (SOTRs) and compare these rates with those in immunocompetent patients. Materials and Methods: A retrospective observational study included cSCC cases from the University Hospital Reina Sofía in Córdoba, Spain, between 2002 and 2019. Demographic, clinical, and histopathological data were collected. Local recurrence and metastasis rates were analyzed, along with progression-free survival. Univariate analyses were performed to identify prognostic factors in SOTRs. Results: Among 849 cSCC cases, we found higher rates of local recurrence and metastasis in tumors developed by SOTRs compared to those in immunocompetent individuals. However, no significant differences in local recurrence, metastasis, or progression-free survival were observed between the two groups. Risk factors for adverse outcomes in SOTRs included tumor size > 2 cm, depth > 4 mm, and a higher Clark level. A total of 34.4% of SOTRs developed a second primary cSCC during the follow-up. Conclusions: In our study, cSCCs in SOTRs did not exhibit statistically significant differences in the rates of adverse outcomes compared to immunocompetent patients. The prognosis of cSCCs in SOTRs may be more related to other tumor-dependent risk factors than to the immunosuppression status itself. Future studies are neededto refine risk stratification and follow-up protocols to ensure the optimal management of high-risk cSCC cases, particularly among immunosuppressed patients.
PB MDPI
SN 2077-0383
YR 2023
FD 2023-12-11
LK https://hdl.handle.net/10668/23202
UL https://hdl.handle.net/10668/23202
LA en
NO Escribano-Castillo, L.; Antoñanzas, J.; Roldán-Córdoba, C.; Velez Garcia-Nieto, A.; Aguado-Gil, L. Prognostic Outcomes of Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Retrospective Comparative Cohort Study. J. Clin. Med. 2023, 12, 7619
DS RISalud
RD Apr 18, 2025